Differentiating ovarian cancer stage, histology, and associated prognosis using pretreatment CA125: A study of4,555 patients (456)
Austin Gardner,Daniel Kapp,John Chan
DOI: https://doi.org/10.1016/s0090-8258(22)01678-x
IF: 5.304
2022-08-01
Gynecologic Oncology
Abstract:Objectives: To evaluate the utility of CA-125 expression in differentiating histologic subtypes and their associated prognosis in patients with epithelial ovarian cancers. Methods: Data were abstracted from the Surveillance, Epidemiology, and End Results database from 2010-2015. Chi-square and Kaplan- Meier tests were used for statistical analysis. Results: Of 4,555 women with ovarian cancer, most were aged 55-59 years. White, Asian, and Black patients comprised 80%, 12%, and 7% of the group, respectively (1% other). In patients with information regarding the stage of disease, stage I was present in 42% of patients, stage II in 10%, stage III in 33%, and stage IV in 16%. Most tumor histologies were papillary serous at 40% compared to 27% endometrioid, 19% clear cell, and 14% mucinous. CA-125 levels were elevated in 82% of the overall group. The proportions of White, Asian and Black with elevated CA-125 were 82%, 76%, and 85% (p<0.01), respectively. Total 68%, 82%, 94%, and 95% of patients with stage I, II, III, and IV had elevated CA-125, respectively (p<0.01). Tumors with papillary serous histology had elevated CA-125 in 92% of cases, whereas endometrioid had 84%, clear cell 72%, and mucinous 63% (p<0.001). In the subgroup of those with stage I disease, CA-125 was increased in 68% of women. Of patients with stage I disease and papillary serous histology, 68% had elevated CA-125, while endometrioid had 79%, clear cell 63%, and mucinous 55% (p<0.001). Elevated expression in patients with stage I disease was associated with worsened survival in those with papillary serous histology but not other subtypes (93 vs 76%; p<0.001). The more advanced disease showed no association between decreased survival and increased CA-125 expression regardless of histology type. Conclusions: Pretreatment CA-125 levels were elevated in nearly 70% of stage I epithelial ovarian cancers and more likely in endometrioid and serous histologies versus other cell types. Increased CA-125 expression was associated with worse survival in patients with stage I disease and papillary serous histology but not other subtypes.
oncology,obstetrics & gynecology